Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth.

TitleUsing the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth.
Publication TypeJournal Article
Year of Publication2010
AuthorsMellick AS, Plummer PN, Nolan DJ, Gao D, Bambino K, Hahn M, Catena R, Turner V, McDonnell K, Benezra R, Brink R, Swarbrick A, Mittal V
JournalCancer Res
Volume70
Issue18
Pagination7273-82
Date Published2010 Sep 15
ISSN1538-7445
KeywordsAnimals, Carcinoma, Lewis Lung, Cell Growth Processes, Cell Line, Tumor, Chickens, Endothelial Cells, Gene Expression Profiling, Inhibitor of Differentiation Protein 1, Mice, Mice, Inbred C57BL, Mice, Transgenic, Neovascularization, Pathologic, Stem Cells, Stromal Cells, Up-Regulation
Abstract

Tumor angiogenesis is essential for malignant growth and metastasis. Bone marrow (BM)-derived endothelial progenitor cells (EPC) contribute to angiogenesis-mediated tumor growth. EPC ablation can reduce tumor growth; however, the lack of a marker that can track EPCs from the BM to tumor neovasculature has impeded progress in understanding the molecular mechanisms underlying EPC biology. Here, we report the use of transgenic mouse and lentiviral models to monitor the BM-derived compartment of the tumor stroma; this approach exploits the selectivity of the transcription factor inhibitor of DNA binding 1 (Id1) for EPCs to track EPCs in the BM, blood, and tumor stroma, as well as mature EPCs. Acute ablation of BM-derived EPCs using Id1-directed delivery of a suicide gene reduced circulating EPCs and yielded significant defects in angiogenesis-mediated tumor growth. Additionally, use of the Id1 proximal promoter to express microRNA-30-based short hairpin RNA inhibited the expression of critical EPC-intrinsic factors, confirming that signaling through vascular endothelial growth factor receptor 2 is required for EPC-mediated tumor biology. By exploiting the selectivity of Id1 gene expression in EPCs, our results establish a strategy to track and target EPCs in vivo, clarifying the significant role that EPCs play in BM-mediated tumor angiogenesis.

DOI10.1158/0008-5472.CAN-10-1142
Alternate JournalCancer Res
PubMed ID20807818
PubMed Central IDPMC3058751
Grant ListR01 CA100933 / CA / NCI NIH HHS / United States
R01 CA100933-06 / CA / NCI NIH HHS / United States
R01 CA135417 / CA / NCI NIH HHS / United States